

Takahiro Kodama

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5386972/publications.pdf>

Version: 2024-02-01

84
papers

2,848
citations

201385

27
h-index

189595

50
g-index

86
all docs

86
docs citations

86
times ranked

4874
citing authors

#	ARTICLE	IF	CITATIONS
1	TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF- κ B-inducing kinase-mediated hepatocyte transdifferentiation. <i>Hepatology</i> , 2023, 77, 395-410.	3.6	7
2	Multimomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. <i>Hepatology</i> , 2023, 77, 77-91.	3.6	50
3	Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration. <i>Hepatology Communications</i> , 2022, 6, 281-296.	2.0	5
4	Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver. <i>Hepatology Communications</i> , 2022, 6, 411-422.	2.0	1
5	Reply. <i>Hepatology</i> , 2022, 75, 1058-1058.	3.6	0
6	Reply. <i>Hepatology</i> , 2022, 75, 1341-1341.	3.6	0
7	Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. <i>Cancers</i> , 2022, 14, 883.	1.7	38
8	Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. <i>Hepatology Research</i> , 2022, 52, 298-307.	1.8	31
9	Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. <i>Hepatology Research</i> , 2022, 52, 630-640.	1.8	25
10	Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	1.4	1
11	Ring Finger Protein 125 Is an Anti-Proliferative Tumor Suppressor in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2589.	1.7	5
12	Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy. <i>Hepatology Communications</i> , 2022, 6, 2474-2487.	2.0	6
13	Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis. <i>Hepatology Research</i> , 2022, 52, 824-832.	1.8	10
14	Constitutive Activation of the Tumor Suppressor p53 in Hepatocytes Paradoxically Promotes Non-Cell Autonomous Liver Carcinogenesis. <i>Cancer Research</i> , 2022, 82, 2860-2873.	0.4	22
15	Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy. <i>Cancers</i> , 2022, 14, 3367.	1.7	24
16	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. <i>Journal of Gastroenterology</i> , 2021, 56, 67-77.	2.3	34
17	Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. <i>Hepatology Research</i> , 2021, 51, 517-527.	1.8	10
18	Hepatitis C virus modulates signal peptide peptidase to alter host protein processing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	6

#	ARTICLE	IF	CITATIONS
19	Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
20	Transcriptomics Identify Thrombospondinâ€² as a Biomarker for NASH and Advanced Liver Fibrosis. <i>Hepatology</i> , 2021, 74, 2452-2466.	3.6	71
21	Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 425-446.	2.3	12
22	Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 365-373.	1.8	8
23	Hepatocellular carcinoma occurrence does not differ between interferonâ€based and interferonâ€free treatment with liver histological assessment. <i>Hepatology Research</i> , 2020, 50, 313-320.	1.8	9
24	Clinical outcomes of directâ€acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. <i>Hepatology Research</i> , 2020, 50, 1118-1127.	1.8	15
25	Initial treatment response to transarterial chemoembolization as a predictive factor for Childâ€Pugh class deterioration prior to refractoriness in hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 1275-1283.	1.8	3
26	Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension. <i>Hepatology Research</i> , 2020, 50, 1091-1100.	1.8	1
27	Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. <i>Scientific Reports</i> , 2020, 10, 941.	1.6	18
28	SIRT1 enhances hepatitis virus B transcription independent of hepatic autophagy. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 64-70.	1.0	9
29	DNase II activated by the mitochondrial apoptotic pathway regulates RIP1-dependent non-apoptotic hepatocyte death via the TLR9/IFN-Î² signaling pathway. <i>Cell Death and Differentiation</i> , 2019, 26, 470-486.	5.0	42
30	Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients. <i>Biochemical and Biophysical Research Communications</i> , 2019, 517, 84-88.	1.0	11
31	Exosomal microRNA<sc>s derived from colon cancer cells promote tumor progression by suppressing fibroblast <i>TP</i> expression. <i>Cancer Science</i> , 2019, 110, 2396-2407.	1.7	55
32	GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFÎ² signaling. <i>Nature Communications</i> , 2019, 10, 3882.	5.8	28
33	CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1362.	1.7	18
34	Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. <i>Journal of Gastroenterology</i> , 2019, 54, 449-458.	2.3	6
35	Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation. <i>Hepatology Research</i> , 2019, 49, 1357-1361.	1.8	4
36	Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients. <i>Hepatology Research</i> , 2019, 49, 853-859.	1.8	4

#	ARTICLE	IF	CITATIONS
37	MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23625-23635.	3.3	22
38	Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response. Hepatology Research, 2019, 49, 570-578.	1.8	32
39	Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection. Hepatology, 2018, 68, 380-383.	3.6	18
40	Hepatocellular carcinoma due to a baffle obstruction after the mustard operation: A case report. Hepatology, 2018, 67, 2471-2473.	3.6	2
41	Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10417-E10426.	3.3	47
42	CTGF Mediates Tumor-Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression. Cancer Research, 2018, 78, 4902-4914.	0.4	75
43	Immunological responses against hepatitis B virus in human peripheral blood mononuclear cell-engrafted mice. Biochemical and Biophysical Research Communications, 2018, 503, 1457-1464.	1.0	2
44	Cholesterol Metabolism Is Enhanced in the Liver and Brain of Children With Citrin Deficiency. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2488-2497.	1.8	5
45	Autophagy impairment in pancreatic acinar cells causes zymogen granule accumulation and pancreatitis. Biochemical and Biophysical Research Communications, 2018, 503, 2576-2582.	1.0	10
46	Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatology Research, 2017, 47, 1438-1444.	1.8	36
47	Circulating tricarboxylic acid cycle metabolite levels in citrin-deficient children with metabolic adaptation, with and without sodium pyruvate treatment. Molecular Genetics and Metabolism, 2017, 120, 207-212.	0.5	12
48	Identification of New Tumor Suppressor Genes in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 4089-4101.	0.4	28
49	In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7301-E7310.	3.3	88
50	Spontaneous closure of an intrahepatic arterioportal fistula: A case report. Acta Hepatologica Japonica, 2017, 58, 393-400.	0.0	1
51	Hepatocellular carcinoma in a case of Wilson's disease with non-cirrhotic liver. Acta Hepatologica Japonica, 2017, 58, 519-527.	0.0	1
52	Two-Step Forward Genetic Screen in Mice Identifies RalGTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma. Gastroenterology, 2016, 151, 324-337.e12.	0.6	27
53	Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with SBCapSeq. Nature Biotechnology, 2016, 34, 962-972.	9.4	40
54	p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth. Carcinogenesis, 2016, 37, 972-984.	1.3	40

#	ARTICLE	IF	CITATIONS
55	Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7749-E7758.	3.3	48
56	Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3384-93.	3.3	56
57	Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma. Hepatology Research, 2015, 45, 1023-1033.	1.8	12
58	Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis. Cancer Prevention Research, 2015, 8, 693-701.	0.7	23
59	Invariant natural killer T cell deficiency leads to the development of spontaneous liver inflammation dependent on $\text{I}\beta\text{T}$ cells in mice. Journal of Gastroenterology, 2015, 50, 1124-1133.	2.3	15
60	The combination therapy of $\text{I}\beta\text{Galactosylceramide}$ and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice. International Journal of Cancer, 2013, 133, 1126-1134.	2.3	11
61	Carbamazepine promotes liver regeneration and survival in mice. Journal of Hepatology, 2013, 59, 1239-1245.	1.8	26
62	Valine, the branched-chain amino acid, suppresses hepatitis C virus RNA replication but promotes infectious particle formation. Biochemical and Biophysical Research Communications, 2013, 437, 127-133.	1.0	8
63	Efficacy of Dienogest in Thinning the Endometrium Before Hysteroscopic Surgery. Journal of Minimally Invasive Gynecology, 2013, 20, 790-795.	0.3	21
64	The Bcl-2 Homology Domain 3 (BH3)-only Proteins Bim and Bid Are Functionally Active and Restrained by Anti-apoptotic Bcl-2 Family Proteins in Healthy Liver*. Journal of Biological Chemistry, 2013, 288, 30009-30018.	1.6	14
65	Estrogen therapy initiated at an early age increases bone mineral density in Turner syndrome patients. Endocrine Journal, 2012, 59, 153-159.	0.7	40
66	Interleukin- 1β enhances the production of soluble MICA in human hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2012, 61, 1425-1432.	2.0	17
67	Pancreatic STAT3 Protects Mice against Caerulein-Induced Pancreatitis via PAP1 Induction. American Journal of Pathology, 2012, 181, 2105-2113.	1.9	30
68	Interferon- β suppresses hepatitis B virus enhancer II activity via the protein kinase C pathway. Virology, 2012, 432, 452-459.	1.1	15
69	Bak deficiency inhibits liver carcinogenesis: A causal link between apoptosis and carcinogenesis. Journal of Hepatology, 2012, 57, 92-100.	1.8	54
70	Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death and Differentiation, 2012, 19, 1856-1869.	5.0	59
71	Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. International Journal of Cancer, 2012, 131, 548-557.	2.3	230
72	Efficacy of hormone therapy for osteoporosis in adolescent girls after hematopoietic stem cell transplantation: a longitudinal study. Fertility and Sterility, 2011, 95, 731-735.	0.5	12

#	ARTICLE	IF	CITATIONS
73	Involvement of STAT3-regulated hepatic soluble factors in attenuation of stellate cell activity and liver fibrogenesis in mice. <i>Biochemical and Biophysical Research Communications</i> , 2011, 406, 614-620.	1.0	15
74	Alterations in microRNA expression profile in HCV-infected hepatoma cells: Involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. <i>Biochemical and Biophysical Research Communications</i> , 2011, 412, 92-97.	1.0	88
75	Delayed-onset caspase-dependent massive hepatocyte apoptosis upon fas activation in bak/bax-deficient mice. <i>Hepatology</i> , 2011, 54, 240-251.	3.6	26
76	BH3-only Activator Proteins Bid and Bim Are Dispensable for Bak/Bax-dependent Thrombocyte Apoptosis Induced by Bcl-xL Deficiency. <i>Journal of Biological Chemistry</i> , 2011, 286, 13905-13913.	1.6	78
77	Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 3343-3356.	3.9	138
78	Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet. <i>Journal of Gastroenterology</i> , 2010, 45, 1247-1254.	2.3	35
79	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. <i>Hepatology</i> , 2010, 52, 1310-1321.	3.6	126
80	Thrombocytopenia Exacerbates Cholestasis-Induced Liver Fibrosis in Mice. <i>Gastroenterology</i> , 2010, 138, 2487-2498.e7.	0.6	111
81	The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 52, 698-704.	1.8	320
82	Fatal exacerbation of type B chronic hepatitis triggered by changes in relaxed circular viral DNA synthesis and virion secretion. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 87-93.	1.0	1
83	Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. <i>Hepatology</i> , 2009, 50, 1217-1226.	3.6	106
84	BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. <i>Hepatology</i> , 2009, 50, 1972-1980.	3.6	23